Pluta, Andrzej

A5112473883

Mayo Clinic

Department of Hematological Oncology, Oncology Spec. Hospital, Brzozow, Poland;

Citations 2

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8018-8018

10.1200/jco.2016.34.15_suppl.8018

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Blood | October 20, 2017 | Volume: 130 | Issue: 24 | Pages: 2610-2618

10.1182/blood-2017-06-791228 | PMID 29054911

Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patients with RRMM.